{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:56:49Z","timestamp":1791633409734,"version":"4.3.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Supported by the Union Chimique Belge (UCB)"},{"name":"Supported by the Scientific and Technological Research Council of Turkey (TUBITAK)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10067-021-05648-0","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T06:46:29Z","timestamp":1613717189000},"page":"3169-3174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Patient characteristics and minimal disease activity in psoriatic arthritis: a transcontinental comparison"],"prefix":"10.1007","volume":"40","author":[{"given":"Sibel","family":"Bakirci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem","family":"Ayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ummugulsum","family":"Gazel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Tinazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Solmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esen","family":"Kasapoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Kalyoncu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel Zehra","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"issue":"2","key":"5648_CR1","first-page":"167","volume":"37","author":"E Calabresi","year":"2019","unstructured":"Calabresi E, Monti S, Governato G, Carli L (2019) One year in review 2018: psoriatic arthritis. Clin Exp Rheumatol 37(2):167\u2013178","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"5648_CR2","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2011-200387","volume":"71","author":"V Strand","year":"2012","unstructured":"Strand V, Sharp V, Koenig AS, Park G, Shi Y, Wang B, Zack DJ, Fiorentino D (2012) Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis 71(7):1143\u20131150. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200387","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5648_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.berh.2018.09.006","volume":"32","author":"D Solmaz","year":"2018","unstructured":"Solmaz D, Eder L, Aydin SZ (2018) Update on the epidemiology, risk factors, and disease outcomes of psoriatic arthritis. Best Pract Res Clin Rheumatol 32(2):295\u2013311. https:\/\/doi.org\/10.1016\/j.berh.2018.09.006","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"10","key":"5648_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11926-015-0540-1","volume":"17","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Gelfand JM (2015) Clinical risk factors for the development of psoriatic arthritis among patients with psoriasis: a review of available evidence. Curr Rheumatol Rep 17(10):64. https:\/\/doi.org\/10.1007\/s11926-015-0540-1","journal-title":"Curr Rheumatol Rep"},{"issue":"4 Suppl 98","key":"5648_CR5","first-page":"9","volume":"34","author":"IB McInnes","year":"2016","unstructured":"McInnes IB (2016) Psoriatic arthritis: embracing pathogenetic and clinical heterogeneity? Clin Exp Rheumatol 34(4 Suppl 98):9\u201311","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"5648_CR6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10067-012-2139-5","volume":"32","author":"E Roussou","year":"2013","unstructured":"Roussou E, Chopra S, Ngandu DL (2013) Phenotypic and clinical differences between Caucasian and South Asian patients with psoriatic arthritis living in North East London. Clin Rheumatol 32(5):591\u2013599. https:\/\/doi.org\/10.1007\/s10067-012-2139-5","journal-title":"Clin Rheumatol"},{"issue":"1","key":"5648_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10067-016-3460-1","volume":"36","author":"YY Leung","year":"2017","unstructured":"Leung YY, Fong W, Lui NL, Thumboo J (2017) Effect of ethnicity on disease activity and physical function in psoriatic arthritis in a multiethnic Asian population. Clin Rheumatol 36(1):125\u2013131. https:\/\/doi.org\/10.1007\/s10067-016-3460-1","journal-title":"Clin Rheumatol"},{"issue":"6","key":"5648_CR8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s11926-007-0074-2","volume":"9","author":"DD Gladman","year":"2007","unstructured":"Gladman DD (2007) Axial disease in psoriatic arthritis. Curr Rheumatol Rep 9(6):455\u2013460. https:\/\/doi.org\/10.1007\/s11926-007-0074-2","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"5648_CR9","first-page":"586","volume":"13","author":"DD Gladman","year":"1986","unstructured":"Gladman DD, Anhorn KA, Schachter RK, Mervart H (1986) HLA antigens in psoriatic arthritis. J Rheumatol 13(3):586\u2013592","journal-title":"J Rheumatol"},{"issue":"2","key":"5648_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/rheumatology\/kew375","volume":"56","author":"U Kalyoncu","year":"2017","unstructured":"Kalyoncu U, Bayindir O, Ferhat Oksuz M, Dogru A, Kimyon G, Tarhan EF, Erden A, Yavuz S, Can M, Cetin GY, Kilic L, Kucuksahin O, Omma A, Ozisler C, Solmaz D, Bozkirli ED, Akyol L, Pehlevan SM, Gunal EK, Arslan F, Yilmazer B, Atakan N, Aydin SZ (2017) The psoriatic arthritis registry of Turkey: results of a multicentre registry on 1081 patients. Rheumatology (Oxford, England) 56(2):279\u2013286. https:\/\/doi.org\/10.1093\/rheumatology\/kew375","journal-title":"Rheumatology (Oxford, England)"},{"issue":"1","key":"5648_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69(1):48\u201353. https:\/\/doi.org\/10.1136\/ard.2008.102053","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"5648_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","volume":"13","author":"G Schett","year":"2017","unstructured":"Schett G, Lories RJ, D'Agostino MA, Elewaut D, Kirkham B, Soriano ER, McGonagle D (2017) Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol 13(12):731\u2013741. https:\/\/doi.org\/10.1038\/nrrheum.2017.188","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"5648_CR13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/03009740802609558","volume":"38","author":"JC Nossent","year":"2009","unstructured":"Nossent JC, Gran JT (2009) Epidemiological and clinical characteristics of psoriatic arthritis in northern Norway. Scand J Rheumatol 38(4):251\u2013255. https:\/\/doi.org\/10.1080\/03009740802609558","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"5648_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41584-018-0006-8","volume":"14","author":"J Feld","year":"2018","unstructured":"Feld J, Chandran V, Haroon N, Inman R, Gladman D (2018) Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nat Rev Rheumatol 14(6):363\u2013371. https:\/\/doi.org\/10.1038\/s41584-018-0006-8","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"5648_CR15","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3899\/jrheum.171094","volume":"45","author":"PJ Mease","year":"2018","unstructured":"Mease PJ, Palmer JB, Liu M, Kavanaugh A, Pandurengan R, Ritchlin CT, Karki C, Greenberg JD (2018) Influence of axial involvement on clinical characteristics of psoriatic arthritis: analysis from the corrona psoriatic arthritis\/spondyloarthritis registry. J Rheumatol 45(10):1389\u20131396. https:\/\/doi.org\/10.3899\/jrheum.171094","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05648-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05648-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05648-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T10:12:12Z","timestamp":1626689532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05648-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["5648"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05648-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"11 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sibel Zehra Aydin received honoraria from Abbvie, Celgene, UCB, Novartis, Jannsen, Pfizer, and Sanofi. The other authors have disclosed no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}